How long has nurtec been on the market and how safe is it?

Short answer:
- How long on the market: Nurtec ODT (the brand name for rimegepant) was approved by the U.S. FDA in February 2020 for acute treatment of migraine in adults. So, it has been available in the U.S. since early 2020 (about 6+ years as of 2026). In other countries the timing varies by approval.

- How safe is it: For most people, Nurtec ODT is considered safe and well tolerated. It is a CGRP receptor antagonist (gepant) and is used to treat a migraine attack acutely rather than as a daily preventive.

What to know about safety (high level):
- Common side effects reported in trials: some people experience nausea, dry mouth, and mild stomach/intestinal discomfort. These are usually not severe.
- Serious side effects are uncommon, but as with any medicine, rare reactions can occur.
- Drug interactions: rimegepant is processed by liver enzymes (CYP3A4 and CYP2C9). Strong inhibitors or inducers of these enzymes can affect levels of the medicine, so dose adjustments or monitoring may be needed if you’re taking certain other drugs.
- Liver disease: individuals with significant liver problems may need special consideration; check with a clinician.
- Pregnancy/breastfeeding: discuss with a healthcare provider as with any migraine medicine.
- It does not carry the same cardiovascular risks as some older migraine medicines (like triptans) because it does not cause vasoconstriction, but always use as directed.

If you’d like, I can pull the latest FDA labeling or patient information insert to give you the exact listed side effects and any specific cautions. Also, if you tell me your country, I can note the local approval status and any country-specific safety notes.